Fatima T. Zehra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fatima T. Zehra has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Abdul Qadir Nawabi
Department of Cardiology, Zhongda Hospital Southeast University, Nanjing, China
1 shared publication - Kiran Abbas
Department of Medicine, Jinnah Postgraduate Medical Centre, Karachi, PAK
1 shared publication - Lijuan Chen
Cardiology, Zhongda Hospital Southeast University, Nanjing, CHN
1 shared publication - Naveed Shaikh
Cardiology, National Institute of Cardiovascular Diseases, Karachi, PAK
1 shared publication - Wardah Hassan
Dow University of Health Sciences, Karachi, Pakistan
1 shared publication
Latest Publications
- Open Access
- 5 March 2022
- Published by Springer Nature in Cureus
- Vol. 14 (3) , e22874
Is Colchicine a New Game-Changer in Patients With Acute Coronary Syndrome?
Colchicine, an anti-inflammatory drug, was declared as a potently cheap and effective drug in treating atherosclerosis. This report is a detailed understanding and an in-depth interpretation of the colchicine cardiovascular outcomes trial (COLCOT) that has taken place in recent years. It is a secondary quantitative study that has reviewed studies discussing the role of colchicine in myocardial infarction, inflammation, ST-elevation myocardial infarction, and in general, acute coronary syndrome (ACS). Different trials statistically proved colchicine's role in ACS by lowering the levels of high c-reactive protein, decreasing low attenuation plaque volume, and stabilizing plaque. Hence, in other words, it has been revealed that this drug has potential in the management of ACS. Colchicine reported promising results in reducing the risk of recurrent myocardial infarction, stroke, and sudden cardiac arrest, playing a massive role in lowering inflammation and the mortality caused by cardiovascular diseases.
- 5 March 2022
- Published by Springer Nature in Cureus
- Vol. 14 (3) , e22874
Open AccessIs Colchicine a New Game-Changer in Patients With Acute Coronary Syndrome?
Colchicine, an anti-inflammatory drug, was declared as a potently cheap and effective drug in treating atherosclerosis. This report is a detailed understanding and an in-depth interpretation of the colchicine cardiovascular outcomes trial (COLCOT) that has taken place in recent years. It is a secondary quantitative study that has reviewed studies discussing the role of colchicine in myocardial infarction, inflammation, ST-elevation myocardial infarction, and in general, acute coronary syndrome (ACS). Different trials statistically proved colchicine's role in ACS by lowering the levels of high c-reactive protein, decreasing low attenuation plaque volume, and stabilizing plaque. Hence, in other words, it has been revealed that this drug has potential in the management of ACS. Colchicine reported promising results in reducing the risk of recurrent myocardial infarction, stroke, and sudden cardiac arrest, playing a massive role in lowering inflammation and the mortality caused by cardiovascular diseases.